Evotec (NASDAQ:EVO) Reaches New 12-Month Low at $5.10

Shares of Evotec SE (NASDAQ:EVO) reached a new 52-week low during trading on Wednesday . The stock traded as low as $5.10 and last traded at $5.18, with a volume of 512534 shares changing hands. The stock had previously closed at $7.65.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on EVO shares. Royal Bank of Canada upgraded shares of Evotec from a “sector perform” rating to an “outperform” rating in a research report on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a “hold” rating to a “buy” rating in a research note on Friday, April 12th.

Evotec Stock Performance

The business’s 50 day simple moving average is $7.37 and its 200-day simple moving average is $8.71.

Institutional Trading of Evotec

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC bought a new stake in shares of Evotec during the 4th quarter worth about $25,000. Optiver Holding B.V. raised its holdings in shares of Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after purchasing an additional 69,936 shares in the last quarter. Finally, Mubadala Investment Co PJSC bought a new stake in shares of Evotec in the 4th quarter worth approximately $53,931,000. 5.81% of the stock is currently owned by institutional investors.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.